The phase III ASCENT study compared the efficacy of sacituzumab govitecan-hziy to single-agent chemotherapy (physician’s choice) in patients with metastatic triple-negative breast cancer. Final results from the trial were recently published by Bardia et al in the Journal of Clinical Oncology.
